DOI QR코드

DOI QR Code

Primary Extranodal Non-Hodgkin's Lymphoma: Clinicopathological Features, Survival and Treatment Outcome in Two Cancer Centers of Southern Turkey

  • Mertsoylu, Huseyin (Department of Medical Oncology, Faculty of Medicine, Baskent University) ;
  • Muallaoglu, Sadik (Department of Medical Oncology, Faculty of Medicine, Baskent University) ;
  • Besen, Ayberk Ali (Department of Medical Oncology, Adana Numune Training and Research Hospital) ;
  • Erdogdu, Suleyman (Department of Medical Oncology, Mersin University Faculty of Medicine) ;
  • Sezer, Ahmet (Department of Medical Oncology, Faculty of Medicine, Baskent University) ;
  • Sedef, Ali Murat (Department of Medical Oncology, Faculty of Medicine, Baskent University) ;
  • Kose, Fatih (Department of Medical Oncology, Faculty of Medicine, Baskent University) ;
  • Arican, Ali (Department of Medical Oncology, Mersin University Faculty of Medicine) ;
  • Ozyilkan, Ozgur (Department of Medical Oncology, Faculty of Medicine, Baskent University)
  • Published : 2014.09.15

Abstract

Background: The aim of this study was to assess the epidemiological and clinicopathological characteristics of primary extranodal non-Hodgkin's lymphoma (pENL) patients, focusing on treatment and survival outcome. Materials and Methods: Between October 2003 and March 2012, 802 patients with non-Hodgkin's lymphoma (NHL) were diagnosed and treated in two different cancer centers of Southern Turkey. Results: pENL, constituted 12.4% (100/802) of all NHL studied during this period. Median age of the patients was 56 years (range 17-87 years) and the male: female distribution was 3:2. Eighty-five of 100 patients (85%) were in stage I/II, 9/100 (9%) in stage III, whereas 6/100 (6%) were in stage IV. Head and neck constituted the most common site (51/100, 51%), followed by gastrointestinal tract (GIL) (37/100, 37%), and cerebrum (CL) (5/100, 5%). Diffuse large B cell lymphoma (DLBCL) was the most common histological type, observed in 53% of patients, followed by marginal zone extranodal lymphoma (13%). Most of patients (76%) received a CHOP containing regimen. Complete remission (CR) were achieved in 71% of patients. The median follow-up duration of all patients was reported as 37.6 months (range, 0.8-165 months). This period was reported as 137.5 months (range, 117.5-1578.6 months) in gastrointestinal lymphoma (GIL) patients, 119.0 months (range, 91.8-146.1 months) in head and neck lymphoma (HNL) patients, and 18.4 months (range, 12.6-24.1 months) in cerebral lymphoma (CL) patients. Conclusions: Head and neck, and the gastrointestinal tract were the two most common extranodal sites observed. Histologically DLBC accounted for the majority of cases. Most patients were on earlier stages, had low-low intermediate IPI scores and had a favorable prognosis.

Keywords

Extranodal lymphoma;non-Hodgkin's lymphoma;clinicopathological characteristics

References

  1. Anderson JR, Armitage JO, Weisenburger DD (1998). Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol, 9, 717-20. https://doi.org/10.1023/A:1008265532487
  2. Arora N, Manipadam MT, Pulimood A, et al (1998). Gastrointestinal lymphomas: Pattern of distribution and histological subtypes: 10 years' experience in a tertiary centre in South India. Ind J Pathol Microbiol, 54, 712-9.
  3. Carbone PP, Kaplan HS, Musshoff K, et al (1971). Report of the Committee on Hodgkin!s disease Staging Classification. Cancer Res, 31, 1860-1.
  4. Chen W, Tsai W, Chao T (2010). The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol, 89, 553-62. https://doi.org/10.1007/s00277-009-0870-z
  5. Chiu BC, Weisenburger DD (2003). An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma, 4, 161-8. https://doi.org/10.3816/CLM.2003.n.025
  6. d'Amore F, Christensen BE, Brincker H, et al (1991). Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer, 27, 1201-8. https://doi.org/10.1016/0277-5379(91)90081-N
  7. Dawson IP, Cornes JS, Morson BC (1961). Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg, 49, 80-9. https://doi.org/10.1002/bjs.18004921319
  8. Freeman C, Berg JW, Cutler SJ (1972). Occurrence and prognosis of extranodal lymphomas. Cancer, 29, 252-60. https://doi.org/10.1002/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#
  9. Fujita A, Tomita N, Fujita H, et al (2009). Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan. Med Oncol, 26, 49-54. https://doi.org/10.1007/s12032-008-9080-0
  10. Groves FD, Linet MS, Travis LB, et al (2000). Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst, 92, 1240-51. https://doi.org/10.1093/jnci/92.15.1240
  11. Krol AD, le Cessie S, Snijder S, et al (2003). Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West populatin-based NHL registry. Ann Oncol, 14, 131-9. https://doi.org/10.1093/annonc/mdg004
  12. Lal A, Bhurgri Y, Vaziri I, et al (2008). Extranodal non-Hodgkin's lymphomas- a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas. Asian Pac J Cancer Prev, 9, 453-8.
  13. Mihaljevic B, Jancic-Nedeljkov R, Vujicic V, et al (2006). Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience. Med Oncol, 6, 23, 225-35. https://doi.org/10.1385/MO:23:2:225
  14. Newton R, Ferlay J, Beral V, Devesa SS (1997). The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extranodal sites. Int J Cancer, 72, 923-30. https://doi.org/10.1002/(SICI)1097-0215(19970917)72:6<923::AID-IJC1>3.0.CO;2-R
  15. Otter R, Gerrits WB, vd Sandt MM, et al (1989). Primary nodal and extranodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol, 25, 1203-10. https://doi.org/10.1016/0277-5379(89)90416-1
  16. Padhi S, Paul TR, Challa S, et al (2012). Primary extra nodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pac J Cancer Prev, 13, 4889-95 https://doi.org/10.7314/APJCP.2012.13.10.4889
  17. Singh D, Kumar L, Goyal H (2003). Primary extranodal non-Hodgkin's lymphoma in northern India. Proc Am Soc Clin Oncol, 22, 2457.
  18. Vose J, Armitage J, Weisenburger D (2008). International T-cell lymphoma project. international peripheral t-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol, 26, 4124-30. https://doi.org/10.1200/JCO.2008.16.4558
  19. Yang QP, Zhang WY, Yu JB, et al (2011). Subtype distribution of lymphomas in southwest china: analysis of 6,382 cases using WHO classification in a single institution. Diagnostic Pathology, 6, 77. https://doi.org/10.1186/1746-1596-6-77
  20. Yaqo RT, Hughson Md, Sulayvani FK, et al (2011). Malignant lymphoma in northern Iraq: A retrospective analysis of 270 cases according to the world health organization classification. Ind J Cancer, 48, 446-51. https://doi.org/10.4103/0019-509X.92276

Cited by

  1. Head and neck extra nodal NHL (HNENL) - Treatment Outcome and Pattern of failure - A Single Institution Experience vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6267
  2. Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2879